US Edition
Published • loading... • Updated
Eli Lilly Builds $1.5 Billion Stockpile of Weight-Loss Pill Ahead of FDA Decision
Eli Lilly's $1.5 billion stockpile of orforglipron reflects readiness for high demand and aims to prevent supply shortages seen in the GLP-1 market from 2022 to 2024.
Summary by CNBC
7 Articles
7 Articles
Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus
Eli Lilly shares rose 1.8% to $1,033.23 in late morning New York trade after Chinese regulators approved mirikizumab for Crohn’s disease and ulcerative colitis. Investors are watching a Feb. 13 ex-dividend date and an expected U.S. decision in April on Lilly’s oral weight-loss pill. Novo Nordisk shares slipped as it announced plans to launch Wegovy in vials. The post Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focu…
Novo Nordisk will begin to market Wegovy, its flagship drug, in vials, abandoning the exclusivity of the plastic injector pens it used so far. This will mean a key strategic change in its struggle to master the market for weight loss drugs. Read
Coverage Details
Total News Sources7
Leaning Left1Leaning Right0Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
